DDX6 overexpression was observed in 60% of gastric cancer samples and 83% of FGFR2-positive cases, and DDX6 knockdown reduced FGFR2 and HER2 protein expression without affecting mRNA levels [39]. The gene discussed is ERBB2; the disease is gastric cancer.